Cost considerations in the management of atrial fibrillation – impact of dronedarone
نویسندگان
چکیده
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent.
منابع مشابه
Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation
INTRODUCTION Dronedarone, a benzofuran derivative with a structure similar to amiodarone, has been developed as a potential therapy for patients with atrial fibrillation. AIM To review the published evidence regarding the efficacy and safety of dronedarone use in patients with atrial fibrillation. EVIDENCE REVIEW Available evidence suggests that dronedarone 400 mg orally twice daily can len...
متن کاملDronedarone for the management of atrial fibrillation.
Atrial fibrillation is a common arrhythmia associated with increased cardiovascular mortality and morbidity including stroke, heart failure and hospitalisations. Major studies on atrial fibrillation have shown no significant difference between rhythm and rate control in terms of mortality. However, rate control treatment may be insufficient to prevent morbidity in a number of patients. Amiodaro...
متن کاملDronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation
Atrial fibrillation (AF) is a supraventricular arrhythmia that leads to a decrease in cardiac output and impairs cardiac function and quality of life. Dronedarone has an atrial-selective property and has been used for management of AF in humans, but limited information is available in dogs. This study was designed to evaluate efficacy of dronedarone in attenuating the duration of AF in dog mode...
متن کاملDronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Dronedarone is a new antiarrhythmic agent that was recently approved for the prevention of cardiovascular hospitalization driven by atrial fibrillation/flutter. Its approval was based largely on the results of the ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any ...
متن کاملDronedarone for atrial fibrillation: a new therapeutic agent
Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone i...
متن کامل